Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.
Matoba Y, Zarrella DT, Pooladanda V, Azimi Mohammadabadi M, Kim E, Kumar S, Xu M, Qin X, Ray LJ, Devins KM, Kumar R, Kononenko A, Eisenhauer E, Veillard IE, Yamagami W, Hill SJ, Sarosiek KA, Yeku OO, Spriggs DR, Rueda BR. Matoba Y, et al. Among authors: rueda br. Br J Cancer. 2024 May;130(9):1463-1476. doi: 10.1038/s41416-024-02621-x. Epub 2024 Mar 4. Br J Cancer. 2024. PMID: 38438589 Free PMC article.
Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
Groeneweg JW, Hernandez SF, Byron VF, DiGloria CM, Lopez H, Scialabba V, Kim M, Zhang L, Borger DR, Tambouret R, Foster R, Rueda BR, Growdon WB. Groeneweg JW, et al. Among authors: rueda br. Clin Cancer Res. 2014 Dec 15;20(24):6517-6528. doi: 10.1158/1078-0432.CCR-14-1647. Epub 2014 Oct 7. Clin Cancer Res. 2014. PMID: 25294905 Free PMC article.
Understanding and Targeting Apoptotic Pathways in Ovarian Cancer.
Al-Alem LF, Baker AT, Pandya UM, Eisenhauer EL, Rueda BR. Al-Alem LF, et al. Among authors: rueda br. Cancers (Basel). 2019 Oct 24;11(11):1631. doi: 10.3390/cancers11111631. Cancers (Basel). 2019. PMID: 31652965 Free PMC article. Review.
Galectins and Ovarian Cancer.
Shimada C, Xu R, Al-Alem L, Stasenko M, Spriggs DR, Rueda BR. Shimada C, et al. Among authors: rueda br. Cancers (Basel). 2020 May 31;12(6):1421. doi: 10.3390/cancers12061421. Cancers (Basel). 2020. PMID: 32486344 Free PMC article. Review.
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
Wan C, Keany MP, Dong H, Al-Alem LF, Pandya UM, Lazo S, Boehnke K, Lynch KN, Xu R, Zarrella DT, Gu S, Cejas P, Lim K, Long HW, Elias KM, Horowitz NS, Feltmate CM, Muto MG, Worley MJ Jr, Berkowitz RS, Matulonis UA, Nucci MR, Crum CP, Rueda BR, Brown M, Liu XS, Hill SJ. Wan C, et al. Among authors: rueda br. Cancer Res. 2021 Jan 1;81(1):158-173. doi: 10.1158/0008-5472.CAN-20-1674. Epub 2020 Nov 6. Cancer Res. 2021. PMID: 33158814 Free PMC article.
Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions.
Lynch KN, Liu JF, Kesten N, Chow KH, Shetty A, He R, Afreen MF, Yuan L, Matulonis UA, Growdon WB, Muto MG, Horowitz NS, Feltmate CM, Worley MJ Jr, Berkowitz RS, Crum CP, Rueda BR, Hill SJ. Lynch KN, et al. Among authors: rueda br. Cancers (Basel). 2021 May 3;13(9):2195. doi: 10.3390/cancers13092195. Cancers (Basel). 2021. PMID: 34063609 Free PMC article.
Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.
Zhang S, Yan C, Millar DG, Yang Q, Heather JM, Langenbucher A, Morton LT, Sepulveda S, Alpert E, Whelton LR, Zarrella DT, Guo M, Minogue E, Lawrence MS, Rueda BR, Spriggs DR, Lu W, Langenau DM, Cobbold M. Zhang S, et al. Among authors: rueda br. Cancer Res. 2022 Mar 1;82(5):773-784. doi: 10.1158/0008-5472.CAN-21-2200. Cancer Res. 2022. PMID: 34965933
148 results